Cargando…

Activation of AHR by ITE improves cardiac remodelling and function in rats after myocardial infarction

AIMS: Left ventricular remodelling subsequent to myocardial infarction (MI) constitutes a pivotal underlying cause of heart failure. Intervention with the nontoxic endogenous aryl hydrocarbon receptor (AHR) agonist 2‐(1′H‐indole‐3′‐carbonyl)‐thiazole‐4‐carboxylic acid methyl ester (ITE) in the acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Xiaoyan, Liu, Weiqiang, Chu, Yong, Zhang, Hailin, Zeng, Lishan, Lin, Yifei, Kang, Kai, Peng, Feng, Lin, Jinxiu, Huang, Chunkai, Chai, Dajun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682871/
https://www.ncbi.nlm.nih.gov/pubmed/37798907
http://dx.doi.org/10.1002/ehf2.14532
_version_ 1785151070538825728
author Lin, Xiaoyan
Liu, Weiqiang
Chu, Yong
Zhang, Hailin
Zeng, Lishan
Lin, Yifei
Kang, Kai
Peng, Feng
Lin, Jinxiu
Huang, Chunkai
Chai, Dajun
author_facet Lin, Xiaoyan
Liu, Weiqiang
Chu, Yong
Zhang, Hailin
Zeng, Lishan
Lin, Yifei
Kang, Kai
Peng, Feng
Lin, Jinxiu
Huang, Chunkai
Chai, Dajun
author_sort Lin, Xiaoyan
collection PubMed
description AIMS: Left ventricular remodelling subsequent to myocardial infarction (MI) constitutes a pivotal underlying cause of heart failure. Intervention with the nontoxic endogenous aryl hydrocarbon receptor (AHR) agonist 2‐(1′H‐indole‐3′‐carbonyl)‐thiazole‐4‐carboxylic acid methyl ester (ITE) in the acute phase of MI has been shown to ameliorate cardiac function, but its role in the chronic phase remains obscured. This study explores the beneficial role of ITE in delaying the progression of heart failure in the chronic phase of MI. METHODS AND RESULTS: MI rats established by ligating the left anterior descending coronary artery were treated with the indicated concentration of the AHR agonist ITE or vehicle alone. Echocardiography was performed to determine cardiac structure and function; myocardial morphology and fibrosis were observed by haematoxylin and eosin and Masson's trichrome staining; serum biochemical indices, BNP, and inflammatory cytokine levels were detected by enzyme‐linked immunosorbent assay; F4/80(+)iNOS(+)M1 macrophages and F4/80(+)CD206(+)M2 macrophages were detected by immunofluorescence; the terminal deoxynucleotidyl transferase‐mediated dUTP nick end labelling assay was used to detect the apoptosis of cardiomyocytes; ultrastructural changes in myocardial tissue were observed by transmission electron microscopy; and Cyp1a1, Akt, P‐Akt, p70S6K, P‐p70S6K, Bcl‐2, Bax, caspase‐3, and cleaved caspase‐3 protein levels were determined via Western blotting. We found that therapy with the AHR agonist ITE rescued cardiac remodelling and dysfunction in rats with MI and attenuated myocardial fibrosis, inflammation, and mitochondrial damage. Further studies confirmed that ITE dose‐dependently improved myocardial cell apoptosis after MI, as demonstrated by reduced levels of the apoptosis‐related proteins cleaved caspase‐3 and Bax but increased expression levels of Bcl‐2. These effects were attributed to ITE‐induced activation of AHR receptors, leading to the down‐regulation of Akt and p70S6K phosphorylation. CONCLUSIONS: The AHR agonist ITE alleviates cardiomyocyte apoptosis through the Akt/p70S6K signalling pathway, thereby rescuing left ventricular adverse remodelling and cardiac dysfunction after MI.
format Online
Article
Text
id pubmed-10682871
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106828712023-11-30 Activation of AHR by ITE improves cardiac remodelling and function in rats after myocardial infarction Lin, Xiaoyan Liu, Weiqiang Chu, Yong Zhang, Hailin Zeng, Lishan Lin, Yifei Kang, Kai Peng, Feng Lin, Jinxiu Huang, Chunkai Chai, Dajun ESC Heart Fail Original Articles AIMS: Left ventricular remodelling subsequent to myocardial infarction (MI) constitutes a pivotal underlying cause of heart failure. Intervention with the nontoxic endogenous aryl hydrocarbon receptor (AHR) agonist 2‐(1′H‐indole‐3′‐carbonyl)‐thiazole‐4‐carboxylic acid methyl ester (ITE) in the acute phase of MI has been shown to ameliorate cardiac function, but its role in the chronic phase remains obscured. This study explores the beneficial role of ITE in delaying the progression of heart failure in the chronic phase of MI. METHODS AND RESULTS: MI rats established by ligating the left anterior descending coronary artery were treated with the indicated concentration of the AHR agonist ITE or vehicle alone. Echocardiography was performed to determine cardiac structure and function; myocardial morphology and fibrosis were observed by haematoxylin and eosin and Masson's trichrome staining; serum biochemical indices, BNP, and inflammatory cytokine levels were detected by enzyme‐linked immunosorbent assay; F4/80(+)iNOS(+)M1 macrophages and F4/80(+)CD206(+)M2 macrophages were detected by immunofluorescence; the terminal deoxynucleotidyl transferase‐mediated dUTP nick end labelling assay was used to detect the apoptosis of cardiomyocytes; ultrastructural changes in myocardial tissue were observed by transmission electron microscopy; and Cyp1a1, Akt, P‐Akt, p70S6K, P‐p70S6K, Bcl‐2, Bax, caspase‐3, and cleaved caspase‐3 protein levels were determined via Western blotting. We found that therapy with the AHR agonist ITE rescued cardiac remodelling and dysfunction in rats with MI and attenuated myocardial fibrosis, inflammation, and mitochondrial damage. Further studies confirmed that ITE dose‐dependently improved myocardial cell apoptosis after MI, as demonstrated by reduced levels of the apoptosis‐related proteins cleaved caspase‐3 and Bax but increased expression levels of Bcl‐2. These effects were attributed to ITE‐induced activation of AHR receptors, leading to the down‐regulation of Akt and p70S6K phosphorylation. CONCLUSIONS: The AHR agonist ITE alleviates cardiomyocyte apoptosis through the Akt/p70S6K signalling pathway, thereby rescuing left ventricular adverse remodelling and cardiac dysfunction after MI. John Wiley and Sons Inc. 2023-10-05 /pmc/articles/PMC10682871/ /pubmed/37798907 http://dx.doi.org/10.1002/ehf2.14532 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Lin, Xiaoyan
Liu, Weiqiang
Chu, Yong
Zhang, Hailin
Zeng, Lishan
Lin, Yifei
Kang, Kai
Peng, Feng
Lin, Jinxiu
Huang, Chunkai
Chai, Dajun
Activation of AHR by ITE improves cardiac remodelling and function in rats after myocardial infarction
title Activation of AHR by ITE improves cardiac remodelling and function in rats after myocardial infarction
title_full Activation of AHR by ITE improves cardiac remodelling and function in rats after myocardial infarction
title_fullStr Activation of AHR by ITE improves cardiac remodelling and function in rats after myocardial infarction
title_full_unstemmed Activation of AHR by ITE improves cardiac remodelling and function in rats after myocardial infarction
title_short Activation of AHR by ITE improves cardiac remodelling and function in rats after myocardial infarction
title_sort activation of ahr by ite improves cardiac remodelling and function in rats after myocardial infarction
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682871/
https://www.ncbi.nlm.nih.gov/pubmed/37798907
http://dx.doi.org/10.1002/ehf2.14532
work_keys_str_mv AT linxiaoyan activationofahrbyiteimprovescardiacremodellingandfunctioninratsaftermyocardialinfarction
AT liuweiqiang activationofahrbyiteimprovescardiacremodellingandfunctioninratsaftermyocardialinfarction
AT chuyong activationofahrbyiteimprovescardiacremodellingandfunctioninratsaftermyocardialinfarction
AT zhanghailin activationofahrbyiteimprovescardiacremodellingandfunctioninratsaftermyocardialinfarction
AT zenglishan activationofahrbyiteimprovescardiacremodellingandfunctioninratsaftermyocardialinfarction
AT linyifei activationofahrbyiteimprovescardiacremodellingandfunctioninratsaftermyocardialinfarction
AT kangkai activationofahrbyiteimprovescardiacremodellingandfunctioninratsaftermyocardialinfarction
AT pengfeng activationofahrbyiteimprovescardiacremodellingandfunctioninratsaftermyocardialinfarction
AT linjinxiu activationofahrbyiteimprovescardiacremodellingandfunctioninratsaftermyocardialinfarction
AT huangchunkai activationofahrbyiteimprovescardiacremodellingandfunctioninratsaftermyocardialinfarction
AT chaidajun activationofahrbyiteimprovescardiacremodellingandfunctioninratsaftermyocardialinfarction